A Prospective Multi-Site Observational Study of SARS-CoV-2 Vaccination Immunogenicity in Patients with Hematologic Malignancies [VIP, study data contributed to the CITF Databank]

<b>Background:</b> Individuals with blood cancers have weakened immune systems due to their disease and treatments, putting them at higher risk of death for COVID-19. An effective vaccine is important to protect them from infection; however, major COVID-19 vaccine trials did not include this population. Therefore, it was not known if people with or treated for blood cancers develop a protective antibody response after vaccination, or if it would last as long as in the general population. <br>

<b>Aims of the CITF-funded study:</b> This study aimed to quantify the humoral immune response to the SARS-CoV-2 vaccine and to describe Grade 2-4 adverse events following immunization in patients with hematologic malignancies. <br>

<b>Methods:</b> This cohort study enrolled patients with hematologic malignancies aged 18 and older from hematology clinics in participating hospitals in Edmonton, Montreal, Ottawa, and Toronto. Participants completed an online questionnaire and provided a dried blood spot sample at baseline and during each follow-up—approximately 90, 180, 270, and 360 days after their second COVID-19 vaccine. Blood samples were also collected 28 days after any additional COVID-19 vaccination dose. <br>

<b>Contributed dataset contents:</b> The datasets include 751 participants who completed baseline questionnaires between August 2021 and August 2023. 95% of participants gave one or more blood samples for SARS-CoV-2 serology between September 2021 and February 2023. Variables include data in the following areas of information: demographics (age, gender, race-ethnicity and indigeneity, region, education, occupation), general health (smokes; chronic disease; height and weight; flu vaccine), SARS-CoV-2 vaccination, clinical characteristics, and serology.